Nuveen
AXDX

Nuveen’s Accelerate Diagnostics AXDX Stock Holding History

Nuveen’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25,549
Closed -$476K – 3255
2022
Q1 		$476K Sell
25,549
-18,416
-42% -$524K ﹤0.01% 3031
2021
Q4 		$2.29M Sell
43,965
-815
-2% -$45.4K ﹤0.01% 2505
2021
Q3 		$2.61M Sell
44,780
-5,680
-11% -$370K ﹤0.01% 2544
2021
Q2 		$4.07M Buy
50,460
+5,305
+12% +$422K ﹤0.01% 2344
2021
Q1 		$3.76M Buy
45,155
+790
+2% +$80.1K ﹤0.01% 2309
2020
Q4 		$3.36M Buy
44,365
+1,270
+3% +$114K ﹤0.01% 2258
2020
Q3 		$4.59M Buy
43,095
+22,742
+112% +$3.16M ﹤0.01% 1960
2020
Q2 		$3.08M Sell
20,353
-8,189
-29% -$807K ﹤0.01% 2144
2020
Q1 		$2.38M Sell
28,542
-411
-1% -$57.8K ﹤0.01% 2106
2019
Q4 		$4.89M Sell
28,953
-5,420
-16% -$895K ﹤0.01% 2014
2019
Q3 		$6.38M Sell
34,373
-10,456
-23% -$2.02M ﹤0.01% 1826
2019
Q2 		$10.3M Buy
44,829
+5,130
+13% +$1M ﹤0.01% 1594
2019
Q1 		$8.35M Sell
39,699
-5,011
-11% -$940K 0.04% 442
2018
Q4 		$5.14M Sell
44,710
-7,704
-15% -$1.14M 0.03% 483
2018
Q3 		$12M Sell
52,414
-2,934
-5% -$649K 0.06% 403
2018
Q2 		$12.3M Buy
55,348
+4,499
+9% +$1.01M 0.08% 355
2018
Q1 		$11.6M Sell
50,849
-14,566
-22% -$3.83M 0.08% 359
2017
Q4 		$17.1M Sell
65,415
-7,535
-10% -$1.77M 0.11% 283
2017
Q3 		$16.4M Buy
72,950
+5,678
+8% +$1.39M 0.11% 284
2017
Q2 		$18.4M Sell
67,272
-6,428
-9% -$1.74M 0.12% 251
2017
Q1 		$17.8M Buy
73,700
+957
+1% +$219K 0.11% 266
2016
Q4 		$15.1M Buy
72,743
+2,651
+4% +$629K 0.08% 328
2016
Q3 		$19.1M Sell
70,092
-965
-1% -$213K 0.11% 214
2016
Q2 		$10.2M Buy
71,057
+9,003
+15% +$1.21M 0.06% 346
2016
Q1 		$8.92M Buy
62,054
+7,522
+14% +$1.06M 0.05% 357
2015
Q4 		$11.7M Buy
54,532
+29,137
+115% +$5.32M 0.06% 305
2015
Q3 		$4.11M Buy
+25,395
New +$5.5M 0.02% 537

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Nuveen's AXDX Position: Q2 2022 in Review

Nuveen sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 25,549 shares — an estimated $476K sold.

Nuveen first reported a position in AXDX in Q3 2015 and held it in 27 quarters. The position peaked at $19.1M in Q3 2016. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

  • Nuveen reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 25,549 Accelerate Diagnostics shares in Q2 2022, an estimated $476K.
  • Nuveen first reported a position in Accelerate Diagnostics in Q3 2015 and held it in 27 quarters.
  • Nuveen's Accelerate Diagnostics position peaked at $19.1M in Q3 2016.
  • 74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.